FINWIRES · TerminalLIVE
FINWIRES

Avantor's Turnaround Story Ongoing, Execution Risks Remain, RBC Says

By

Avantor's (AVTR) turnaround narrative merits a constructive view, but that should be balanced against the level of execution still needed, RBC Capital Markets said in a note emailed Friday.

The firm said that while investor expectations and the shares' multiples "have reset," it does not consider consensus estimates and company targets fully de-risked, such as free cash flow guidance, which is an important metric.

The company's outlook of $500 million to $550 million of free cash flow in 2026 "seems difficult to achieve" after $39 million, excluding restructuring costs, in Q1, the note said.

Meanwhile, Avantor's management's focus on improving e-commerce and service levels, as well as branding, is an indication that it is "addressing the right concerns," RBC said.

"Early signals are encouraging, and the Q1 2026 earnings report was the first in a while not accompanied by downward estimate revisions," the note said.

RBC resumed Avantor's coverage with a sector perform rating and a $9 price target.

Price: $7.76, Change: $-0.19, Percent Change: -2.33%

Related Articles

Wire

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Wire

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Wire

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC